Endo International (ENDP) reports quarterly earnings Thursday February 28th. Analysts expect revenue of $738.77 million and eps of $0.59. The revenue estimate implies a 1% decline sequentially. This could be a pivotal earnings report for Endo. In Q3 the company may have raised the bar for itself. Endo delivered revenue of $745.47 million and non-GAAP eps of $0.71. It beat on revenue and non-GAAP eps. In my opinion, its Q3 results were nothing short of remarkable.
The also announced positive Phase 3 studies for CCH in cellulite just prior to announcing its Q3 earnings:
Subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment, as measured by the trial’s primary endpoint (RELEASE-1, p=0.006 & RELEASE-2, p=0.002), which was at least a 2-level composite improvement in cellulite severity in the target buttock at Day 71 as compared to subjects receiving placebo.
In addition, RELEASE-1 passed 8 out of 8 key secondary endpoints and RELEASE-2 passed 7 out of 8 key secondary endpoints. CCH was well-tolerated in the actively-treated subjects with most adverse events (“AES”) being mild to moderate in severity and primarily limited to the local injection area.
If Endo delivers on revenue and earnings expectations then it could help sentiment for the stock. That said, I believe there are three reasons ENDP could soar post earnings. Read more: